Fleischmann KE, Beckman JA, Buller CE, Calkins H, Fleisher LA, Freeman WK, Froehlich JB, Kasper EK, Kersten JR, Robb JF, Valentine RJ
The American Diabetes Association's Standards of Care recommending GLP-1 receptor agonists as preferred second-line agents after metformin and as first-line in patients with high cardiovascular risk create guideline-driven prescription demand that sustains diabetes application dominance
In fact, the labeling for Vyvanse carries a boxed warning of a high potential for abuse and dependence. And substance abuse is noted to be more common in people with eating disorders
Not recommended for use in: Severe gastrointestinal disease including gastroparesis Previous pancreatitis Medullary thyroid carcinoma or history of MEN2 syndrome Caution if concerns of malnourishment and/or underweight More reading...
Start with protein